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Abstract: Silver nanoparticles (AgNPs) have attracted much attention as antimicrobial agents 
and have demonstrated efficient inhibitory activity against various viruses, including human 
immunodeficiency virus, hepatitis B virus, and Tacaribe virus. In this study, we investigated if 
AgNPs could have antiviral and preventive effects in A/Human/Hubei/3/2005 (H3N2) influenza 
virus infection. Madin-Darby canine kidney cells infected with AgNP-treated H3N2 influenza 
virus showed better viability (P,0.05 versus influenza virus control) and no obvious cytopathic 
effects compared with an influenza virus control group and a group treated with the solvent 
used for preparation of the AgNPs. Hemagglutination assay indicated that AgNPs could 
significantly inhibit growth of the influenza virus in Madin-Darby canine kidney cells (P,0.01 
versus the influenza virus control). AgNPs significantly reduced cell apoptosis induced by 
H3N2 influenza virus at three different treatment pathways (P,0.05 versus influenza virus 
control). H3N2 influenza viruses treated with AgNPs were analyzed by transmission electron 
microscopy and found to interact with each other, resulting in destruction of morphologic viral 
structures in a time-dependent manner in a time range of 30 minutes to 2 hours. In addition, 
intranasal AgNP administration in mice significantly enhanced survival after infection with the 
H3N2 influenza virus. Mice treated with AgNPs showed lower lung viral titer levels and minor 
pathologic lesions in lung tissue, and had a marked survival benefit during secondary intranasal 
passage in vivo. These results provide evidence that AgNPs have beneficial effects in preventing 
H3N2 influenza virus infection both in vitro and in vivo, and demonstrate that AgNPs can be 
used as potential therapeutics for inhibiting outbreaks of influenza.
Keywords: silver nanoparticles, influenza virus, H3N2, antiviral activity
Introduction
Among the leading global infections, influenza is a major cause of morbidity and 
 mortality, periodically causing recurrent epidemics or global pandemics that can result 
in approximately 20% of the world’s population becoming ill.1,2 Influenza viruses (IFVs) 
are negative-stranded RNA viruses, belonging to the family Orthomyxoviridae. They 
are classified into different serotypes based on the antigenicity of their hemagglutinin 
(16 subtypes, H1–H16) and neuraminidase (nine subtypes, N1–N9) molecules, but H1, 
H2 and H3, and N1 and N2 are commonly represented in humans.3,4 Antigenic drift 
occurs when small mutations emerge in hemagglutinin or neuraminidase antigens, and 
is distinct from genetic shift whereby completely new strains can emerge when different 
IFV strains recombine with each other.5–7 Either antigenic mutation or reassortment 
can result in novel pathogenic IFV strains with the capacity to cause new epidemics or 
worldwide pandemics.1 Many influenza variants have evolved and have the potential 
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to develop resistance to antiviral drugs. Currently, the two 
main strategies used to control the prevalence of influenza 
are injectable vaccines and antiviral agents. However, IFV 
vaccination would have little efficacy in the early stages of 
an epidemic, especially one generated by genetic shift with 
a new virus subtype.1,8 The two classes of antiviral agents 
widely used against influenza at present are the M2 channel 
blockers (adamantane derivatives) and neuraminidase inhibi-
tors (oseltamivir and zanamivir), but their long-term effec-
tiveness against IFV is debatable and limited by increasing 
emergence of drug resistance and side effects.1,9,10 Given the 
limited ability of currently available treatments to deal with 
an influenza pandemic, there is an ongoing requirement for 
new approaches to reduce virus progression and transmission, 
especially for the development of anti-IFV agents offering 
broad spectrum protection.
Silver nanoparticles (AgNPs) have shown promising 
antibacterial and antifungal activity that is mainly due to 
inhibition of respiratory enzymes by release of Ag+ ions.11,12 
AgNPs are increasingly being explored as antiviral agents 
in viral illnesses, such as human immunodeficiency virus-1, 
hepatitis B virus, herpes simplex virus type 1, Monkeypox 
virus, and Tacaribe virus.13–17 The mechanisms by which 
AgNPs exert their antiviral effects remain unclear. Recently, 
we demonstrated that AgNPs have efficient inhibitory effects 
against H1N1 influenza A virus in Madin-Darby canine 
kidney (MDCK) cells.18 In this study, to determine whether 
these promising results can also be observed for different 
strains of IFV, we explored the therapeutic antiviral effects 
of AgNPs on H3N2 IFV both in vitro and in vivo. We used 
a series of in vitro assays to evaluate the ability of AgNPs to 
prevent virus infection in MDCK cells, and established an 
H3N2 IFV-infected mouse model to investigate their pro-
tective effects in vivo. The results demonstrate that AgNPs 
can interact with H3N2 IFV and efficiently prevent MDCK 
cells and mice from infection with the virus, suggesting 
that AgNPs could be of great interest in the application of 
antivirus offering broad spectrum protection.
Materials and methods
cells and virus
MDCK cells purchased from the American Type Culture 
Collection (ATCC; Manassas, VA, USA) were main-
tained in Dulbecco’s Modified Eagle’s Medium (Gibco, 
Grand Island, NY, USA) supplemented with 10% heat-
inactivated fetal bovine serum (Hyclone, Logan, UT, USA). 
The mouse-adapted influenza A virus (H3N2 subtype A/
Human/Hubei/3/2005) was kindly provided by Professor 
Xulin Chen (Wuhan Institute of Virology, Chinese Acad-
emy of Science, Wuhan, People’s Republic of China). The 
H3N2 IFV was propagated in 10–11-day-old embryonated 
chicken eggs, and egg allantoic fluids were harvested and 
stored at -80°C until use for cell culture and inoculation 
of mice.
Preparation of agNPs
Spherical AgNPs were obtained via an oxidation-reduction 
reaction by adding silver nitrate (2 mL, 100 mM), sodium 
carbonate (0.4 mL, 120 mM), and tannic acid (2 mL, 5.8 mM) 
to a final volume of 50 mL with distilled water, adjusting the 
final pH to 7.4 with 1 M HCl or 5 M NaOH. The mixture was 
then refluxed with vigorous stirring for 2 hours until there 
was no visible change in the pale yellow color, indicating 
formation of AgNPs. The synthesis efficiency of silver was 
calculated by inductively coupled plasma optical emission 
spectrometry or by the following formula:
 
1- Free silver in the synthesized solution
Total silver used for synthesizing
× 100%
Cell viability assay
The toxic effects of AgNPs and the solvent used for their 
AgNP preparation were determined by the Mosmann-based 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay, as in our recent publication.18 Based 
on the results, the solvent and AgNPs at concentrations 
ranging from 6.25 µg/mL to 50 µg/mL had no significant 
toxic effect on cells. In this study, three concentrations, ie, 
12.5, 25, and 50 µg/mL, were used for further assays. For 
the cell viability assay, H3N2 IFV was treated with AgNPs 
for 2 hours prior to infection using MDCK cells for a fur-
ther 2 hours. H3N2 IFV control and solvent groups were 
included as controls after 48 hours of normal incubation 
(n=5 in each group). Cell viability was evaluated by MTT 
assay and cytopathic effects (CPEs) were observed under 
light microscopy.
Hemagglutination assay
To determine the effects of AgNPs on IFV growth, MDCK 
cells were infected with H3N2 IFV that was pretreated with 
AgNPs (12.5, 25, or 50 µg/mL) for 2 hours. As an indica-
tor of growth and replication of the virus and increased 
hemagglutination activity, the cell culture supernatants 
were harvested after 48 hours of incubation to measure 
hemagglutinin titers in 96-well microplates with V-shaped 
bottoms, as described elsewhere.18 An equal volume 
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of 0.5% chicken erythrocytes suspended in phosphate-
buffered saline and cell supernatants was incubated at 
room temperature for 1 hour. Viral titers are presented as 
log
10
/mL. The assay was triplicated containing the IFV and 
solvent controls.
Flow cytometry analysis
It has been reported that IFV can induce cell apoptosis.19 The 
protective effects of AgNPs against cell apoptosis induced by 
H3N2 IFV were determined using flow  cytometry. MDCK 
cells were infected with a mixture of H3N2 virus and AgNPs 
(12.5, 25, or 50 µg/mL) for 1 hour at 4°C.  Following two 
rinses with ice-cold phosphate-buffered saline and incubation 
of binding buffer (phosphate-buffered saline containing 10% 
fetal bovine serum, 0.1 mg/mL transfer RNA and 0.1 mg/mL 
bovine serum albumin) for 30 minutes at room temperature, 
propidium iodide was added and incubated for 30 minutes at 
4°C with protection from light. The cells were then washed 
three times, resuspended in 150 µL of phosphate-buffered 
saline, and subjected to flow cytometric analysis. The preinfec-
tion group (cells infected with virus for 2 hours then incubated 
with 50 µg/mL AgNPs for a further 2 hours) and post-infection 
group (cells incubated with 50 µg/mL AgNPs for 2 hours then 
infected with virus for a further 2 hours) were also performed 
for determining the cell apoptosis in parallel. The assay was 
triplicated containing the IFV and solvent controls.
Immunofluorescence analysis
MDCK cells (1 × 105) were seeded onto cover slips at 37°C 
for 24–48 hours followed by infection with a mixture of 
H3N2 IFV and 50 µg/mL AgNPs for 2 hours. The same 
assay was done in parallel with the different groups, ie, 
the nontreated cell group, IFV control group, the solvent 
control group, preinfection group (infected with virus for 
2 hours then incubated with 50 µg/mL AgNPs for a further 
2 hours) and post-infection group (cells incubated with 
50 µg/mL AgNPs for 2 hours then infected with virus for 
a further 2 hours). When the IFV control group developed 
significant lesions, the cells were fixed with 4% glutaral-
dehyde for 1 hour followed by blocking with 0.5% bovine 
serum albumin in phosphate-buffered saline for another 
hour at room temperature. Following two rinses with cold 
phosphate-buffered saline, the cells were stained with anti-
hemagglutinin isothiocyanate-conjugated antibody (Dako 
Cytomation, England) for 60 minutes at 37°C. The screening 
reagent was then added and incubated for 30 minutes. The 
slides were mounted and visualized under a fluorescence 
microscope (Olympus, Center Valley, PA, USA).
Transmission electron microscopic 
analysis
To illustrate the interaction between AgNPs and H3N2 IFV, 
AgNP-treated H3N2 IFV was negatively stained and morpho-
logically analyzed using a transmission electron microscope 
(TEM; Hitachi, Tokyo, Japan).20 Following treatment of the 
H3N2 IFV with 50 µg/mL AgNPs at various time points 
(30, 60, and 120 minutes), the mixture was attached to the top 
of carbon-coated collodion grids (300 mesh; Nisshin EM Co., 
Ltd., Tokyo, Japan) for 10 minutes. The grids were stained 
with 2% phosphotungstic acid in Sorensen phosphate buffer 
(0.06 M, pH 6.5) for 2 minutes. After rinsing and air-drying 
the slides, the grids were examined by TEM.
In vivo study
Thirty-two 8–10-week-old female BALB/c mice (Labora-
tory Animal Centre of Dalian Medical University, Dalian, 
People’s Republic of China) were randomly divided into four 
groups, ie, a phosphate-buffered saline control group, an 
H3N2 IFV control group, and two post-treatment groups of 
AgNPs and oseltamivir (used as positive controls). All mice 
in the IFV control, AgNP, and oseltamivir treatment groups 
were anesthetized and infected intranasally with 20 µL of 
H3N2 IFV. AgNPs and oseltamivir were administered to the 
anesthetized mice initially 24 hours after infection and every 
24 hours thereafter for a total of three times at concentra-
tions of 5 mg/kg and 20 mg/kg, respectively, via intranasal 
absorption. Clinical signs, changes in body weight, and 
mortality were recorded daily up to day 14. Mice in the IFV 
control group and the other three groups were sacrificed 
on day 6 by isoflurane overdose. The lungs were extracted, 
washed in 2 mM ethylenediaminetetraacetic acid (EDTA) 
phosphate-buffered saline, and kept at -80°C until further 
experiments. Parts of lung tissue were homogenized and 
administered intranasally for the second passage of mouse 
infection. All experiments were approved and guided by the 
Institutional Animal Care and Use Committee, School of 
Medicine, Dalian University.
lung ratio calculation and virus  
titers in mice
Following sacrifice of the mice, three mice were chosen at 
random and their lungs were weighed for the lung index using 
the equation, (weight of the lung/weight of the mouse) × 100%. 
Lung homogenates were centrifuged at 10,000 g for 10  minutes 
before the supernatant was collected for determination of virus 
titer by the standard hemagglutinin assay as described above.
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Analysis of lung histology
After sacrifice, the middle lobe of the right lung from each 
mouse was removed and fixed in 10% formaldehyde solution 
for 24–48 hours. The tissues were dehydrated in a graded 
ethanol series and embedded in paraffin. Sections were 
embedded in wax and cut into 5 µm slices for hematoxylin 
and eosin staining, and pathologic changes were studied by 
light microscopy.
Statistical analysis
All data are shown as the mean ± standard deviation. 
 One-way analysis of variance was used to identify statisti-
cally significant differences between groups. Statistical 
significance was set at P,0.05.
Results
Characterization and stability of AgNPs
The AgNPs generated in this study were assessed by TEM, 
with multiple TEM images chosen at random and over 
300 nanoparticles measured to determine their size. The 
monodispersed AgNPs had a mean diameter of around 
9.5 nm with a standard deviation of approximately 0.8 nm 
on observation by TEM (Figure 1). The synthesis efficiency 
of pure silver was around 99.99%, and final concentrations 
of AgNPs and silver were 400 µg/mL and 0.8 µg/mL respec-
tively. The AgNPs had a very narrow size distribution and 
were found to be stable over 6 months at room temperature 
without obvious particle precipitation.
Inhibitory effects of AgNPs  
against h3N2 IFV
To study the inhibitory effects of AgNPs against H3N2 IFV, 
percentages of surviving MDCK cells were determined by 
MTT assay. Following treatment of the virus with AgNPs 
at different concentrations (12.5, 25, or 50 µg/mL) for 
2 hours before incubation with MDCK cells for 2 hours, 
the cell viability was 53.46%±2.98%, 68.23%±5.11%, and 
80.27%±1.43%, respectively, following 48 hours of nor-
mal incubation (Figure 2A), while the survival rates were 
21.66%±4.72% and 23.92%±6.32%, respectively, in the IFV 
control cells and cells treated with a mixture of virus and 
solvent. The data from the AgNP groups and those from the 
IFV control group were significantly different (P,0.01). 
In addition, the anti-H3N2 IFV effects of the AgNPs were 
observed under a light microscope, and no significant CPEs 
were observed either in the normal cell group (Figure 2B) 
or the solvent cell group (Figure 2C), indicating that the 
solvent used for the AgNPs was not toxic to MDCK cells. 
However, typical CPEs were observed in the IFV control 
group (Figure 2D) and in the cells treated with a mixture 
of H3N2 IFV and solvent (Figure 2E), the infected cell 
monolayer shrank and became round, broke off, detached 
from the cell culture flask, and floated in the medium. No 
significant CPEs were detected in cells infected with a mix-
ture of virus and 50 µg/mL AgNPs (Figure 2F), indicating 
that AgNPs at this concentration had inhibitory effects on 
H3N2 IFV infection.
agNPs inhibit growth of IFV in vitro
To understand further the protective effects of AgNPs, we 
determined the inhibitory effects of AgNPs on viral growth 
by hemagglutinin assay. The lowest concentration of AgNPs 
(12.5 µg/mL) resulted in an approximately two-fold statisti-
cally significant decrease in hemagglutinin activity compared 
with the IFV control (P,0.01, Figure 3). Greater decreases 
in hemagglutinin titer were observed with increasing concen-
trations of AgNPs, indicating that AgNPs could efficiently 
inhibit the growth of IFV in vitro. Hemagglutinin titers did 
2-7.tif
2:43:49 p 11-05-12
TEM Mode: Imaging
20 nm
HV=120.0 kv
Direct Mag: 400,000x
AMT Camera System
Figure 1 TEM analysis of silver nanoparticles. 
Notes: Scale bar, 20 nm; TEM magnification 400,000×. 
Abbreviation: TEM, transmission electron microscopy.
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not differ between cells in the IFV control group and those 
in the mixture of virus and solvent group (P.0.05, Figure 3). 
In addition, similar inhibitory effects were obtained when the 
mixture of H3N2 IFV and AgNPs was used to infect eggs 
(data not shown).
Protective effects of agNPs  
against cell apoptosis
The apoptosis rate of normal cells was 6.31%±2.16%, 
while that in the IFV control cells and cells treated with the 
 solvent and virus were 25.29%±3.66% and 23.96%±2.78%, 
 respectively (Figure 4). After treatment of the virus 
with AgNPs at different concentrations (12.5, 25, or 
50 µg/mL) prior to incubation, apoptosis in MDCK cells 
was 17.15%±4.35%, 12.47%±2.52%, and 8.27%±3.26%, 
respectively; these data showed statistically significant dif-
ferences (P,0.05 versus IFV control). Further, the rate of 
apoptosis in the preinfection and post-infection groups was 
significantly different from that of the IFV control group 
(13.58%±4.86% and 17.47%±5.13%, respectively, P,0.05). 
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Figure 2 agNPs inhibited h3N2 IFV infection of MDcK cells. (A) Treatment of h3N2 IFVs with agNPs at different concentrations (12.5, 25, or 50 µg/ml) for 2 hours prior 
to incubation with MDCK cells for a further 2 hours. Survival percentages of MDCK cells were determined by MTT assay after 48 hours of normal incubation. IFV control 
and solvent group experiments were performed in parallel. (B–F) Cytopathic effects observed under light microscopy. No obvious cytopathic effect was observed in mock 
cells (B) and cells treated with the solvent used for agNP preparation (C). Obvious cytopathic effects were observed in the IFV control (D) and cells treated with a mixture 
of the solvent and virus (E). Minor cytopathic effects were observed in cells treated with the mixture of 50 µg/ml agNPs and virus (F). 
Notes: Values shown are the mean ± standard deviation for three independent experiments (n=5 in each group). The data are significantly different at §§P,0.01 versus IFV 
control. scale bar, 600 µm. 
Abbreviations: agNPs, silver nanoparticles; IFV, influenza virus; MDCK, Madin-Darby canine kidney; 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro mide (MTT).
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These results suggest that AgNPs are able to reduce apoptosis 
induced by H3N2 IFV in MDCK cells.
Analysis by immunofluorescence
To investigate further whether AgNPs could affect infection 
of cells by the virus, an immunofluorescence staining assay 
was done on hemagglutinin protein. Normal cells showed no 
special color and had normal cellular structures  (Figure 5A), 
while extensive specific yellow fluorescence was observed 
in the IFV control cells (Figure 5B) and in cells treated with 
the mixture of virus and solvent (Figure 5C). The cells rolled 
back, became rounded, detached, and fell from the flask. 
However, fluorescence was occasionally seen in cells infected 
with the mixture of AgNPs and H3N2 IFV  (Figure 5D) and in 
the preinfection and post-infection groups (Figure 5E and F). 
Overall, AgNPs show obvious anti-H3N2 IFV activity that 
might be due to their adsorption interference of H3N2 IFVs 
to MDCK cells.
Morphologic abnormalities  
in AgNP-treated virus
Negatively stained H3N2 IFV particles were observed by 
TEM to illustrate the interaction between AgNPs and IFV. 
The IFV control, approximately 80–120 nm, showed typical 
elliptical or spherically shaped normal IFVs containing viral 
matrix and capsid (Figure 6A). After interaction of AgNPs 
with H3N2 IFV for 30 minutes, the viral morphology changed 
slightly, with few AgNPs observed around the edge of the 
virus (Figure 6B); while parts of viral edges were lost after 
60 minutes interaction between AgNPs and virus (Figure 6C). 
The viral morphologic structure was almost destroyed after 
120 minutes of interaction (Figure 6D). These results show 
that AgNPs can interact directly with virus particles and 
destroy morphologic viral structures, leading to disruption 
of viral function in a time-dependent manner.
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Figure 3 agNPs inhibited the growth of h3N2 IFV. Treatment of h3N2 IFVs 
with agNPs at different concentrations (12.5, 25, or 50 µg/ml) for 2 hours prior 
to incubation with MDcK cells for 48 hours. growth of the virus was examined 
by hemagglutinin assay. IFV control and the mixture of virus with the solvent 
experiments were performed in parallel. 
Notes: Values shown are the mean ± standard deviation for three independent 
experiments (n=5 in each group). The data are significantly different at §§P,0.01 
versus IFV control. 
Abbreviations: agNPs, silver nanoparticles; IFV, influenza virus; MDCK, Madin-
Darby canine kidney. HA, hemagglutination.
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Figure 4 agNPs reduced cell apoptosis induced by H3N2 IFV infection. 
(A) Treatment of h3N2 IFVs with agNPs at different concentrations (12.5, 25, 
or 50 µg/ml) for 2 hours prior to incubation with MDcK cells for 48 hours. cell 
apoptosis was determined by flow cytometry assay. IFV control and solvent group 
experiments were performed in parallel. (B) cell apoptosis was detected after 
two treatment pathways: preinfection (cells infected with virus for 2 hours then 
incubated with 50 µg/mL AgNPs for a further 2 hours) and post-infection (cells 
were incubated with 50 µg/ml agNPs for 2 hours then infected with virus for a 
further 2 hours). 
Notes: Values shown are the mean ± standard deviation for three independent 
experiments (n=5 in each group). The data are significantly different at §P,0.05, 
§§P,0.01 versus IFV control. 
Abbreviations: agNPs, silver nanoparticles; IFV, influenza virus; MDCK, Madin-
Darby canine kidney.
International Journal of Nanomedicine 2013:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4109
Inhibition of H3N2 influenza virus by AgNPs
Inhibition of h3N2 IFV infection  
by AgNPs in vivo
Morbidity and mortality were determined to examine the 
potential role of AgNPs in protection against H3N2 IFV 
infection in live animals. All mice in the IFV control group 
had died by day 7 after infection, and showed severe weight 
loss. In contrast, after only three cycles of treatment, the mice 
treated with AgNPs and oseltamivir had survival rates of 
75% and 88%, respectively, even though the surviving mice 
showed visible weight loss compared with the phosphate-
buffered saline control group (Figure 7A and B). To under-
stand better how AgNPs prevent IFV infection, the mouse 
lungs were harvested to detect lung ratios and virus titers. 
The lung ratio in IFV-infected mice was approximately three 
times than that of the phosphate-buffered saline control 
(Figure 7C), and it showed minor changes in the AgNP and 
oseltamivir groups compared with the phosphate-buffered 
saline control group. The lung ratio is a reliable indicator of 
lung lesion levels; at high levels, the cellular inflammatory 
and cytosol permeating could increase inside of lung cells, 
resulting in cell edema and an increase in the lung ratio.21 
The AgNP and oseltamivir groups showed a reduction in 
lung virus titers by .2 log
10
-fold compared with the IFV 
control (Figure 7D). This finding indicates that intranasal 
administration of AgNPs and oseltamivir can protect mice 
from H3N2 IFV infection.
Figure 5 AgNPs inhibited H3N2 IFV binding on MDCK cells, as observed by immunofluorescence staining. (A) Mock cells. (B and C) Extensive fluorescence was observed 
in IFV control and cells treated with the mixture of virus and solvent, respectively. (D) Treatment of virus with 50 µg/ml agNPs for 2 hours prior to incubation with MDcK 
cells. (E and F) No obvious fluorescence was observed in preinfection (cells infected with virus for 2 hours then incubated with 50 µg/ml agNPs for a further 2 hours) and 
post-infection (cells were incubated with 50 µg/mL AgNPs for 2 hours then infected with virus for a further 2 hours), respectively. 
Note: scale bar, 20 µm. 
Abbreviations: AgNPs, silver nanoparticles; IFV, influenza virus; MDCK, Madin-Darby canine kidney.
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In addition, pathologic tissue changes were examined by 
histologic analysis. Compared with the phosphate-buffered 
saline control group (Figure 7Ea), minor changes in the 
structure of the pulmonary alveolus were observed in the 
mice treated with oseltamivir (Figure 7Eb). In mice admin-
istered AgNPs, some lymphocytic infiltration was seen in 
the alveolar septum (Figure 7Ec), and this infiltration was 
more pronounced and accompanied by alveolar wall necrosis 
in mice infected with free IFV (Figure 7Ed). These results 
suggest that AgNPs can inhibit IFV transfection and replica-
tion in the mouse lung. We repeated our in vivo experiment 
and prepared lung homogenates for secondary passage in 
mice. Both AgNPs and oseltamivir were able to increase the 
percentage of surviving mice significantly at 2 weeks after 
infection (Table 1). Taken together, these data suggest that 
intranasal administration of AgNPs can protect mice from 
H3N2 IFV infection in vivo.
Discussion
An influenza pandemic is a serious threat to public health, 
but the antiviral agents currently used for influenza are 
weakened as a result of side effects and the increasing 
emergence of drug-resistant organisms during treatment.9 
Vaccines also have their drawbacks, due to the requirement 
that they closely match the new virus strain, thereby  killing 
the virus efficiently.8 Therefore, there is a high demand 
for new antiviral agents in the treatment and control of 
 influenza. In the present study, we selected a highly patho-
genic IFV strain, ie, H3N2, as the virus model and evaluated 
the  antiviral effects of AgNPs on H3N2 IFV. To this end, 
we performed a series of in vitro assays based on cell culture 
and established an animal model of IFV infection in vivo, 
and demonstrated that AgNPs are potential therapeutics that 
can effectively inhibit IFV infection.
The MTT assay is commonly used to measure cell viabil-
ity because of its sensitivity and rapid response. In this study, 
the viability of MDCK cells significantly increased and no 
obvious CPEs were observed when cells were incubated with 
a mixture of AgNPs and H3N2 IFV as compared with IFV 
control and the solvent group. These results demonstrate 
that AgNPs can prevent MDCK cells from infection by 
H3N2 IFV. In addition, on fluorescence staining analysis, 
no obvious fluorescence was observed in cells treated with 
AgNPs, which investigates that AgNPs may available to 
damage the structure of viral surface so as to inhibit virus 
attachment to host cells. Similarly, it has been shown that 
Figure 6 Transmission electron microscopic analysis of AgNPs-treated H3N2 IFV. Negative staining of viruses was analyzed. (A) Virus control. (B–D) Viral morphologic 
structures were gradually damaged when H3N2 IFV was treated with 50 µg/mL AgNPs for 30 minutes, 90 minutes, and 120 minutes, respectively. 
Note: scale bar, 100 nm. 
Abbreviations: AgNPs, silver nanoparticles; IFV, influenza virus.
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AgNPs can reduce formation of the virus plaque induced 
by Monkeypox virus.16
Influenza virus contains two main functional glycopro-
teins, ie, hemagglutinin and neuraminidase, that wrap around 
an inner core.22 The hemagglutinin protein, a structural com-
ponent of the viral envelope, has hemagglutinating activity 
and contributes to identifying and binding to host membrane 
receptor sites, resulting in entry of the viral capsid and 
genome and infection of the host.23,24 Thus, the  hemagglutinin 
protein might be of interest as a target for antiviral drugs. 
Treatment of H3N2 IFV with AgNPs resulted in marked 
reduction in virus hemagglutinin titers by up to more than 
two log
10
 when cells were incubated with a combination of 
AgNPs and H3N2 IFV. These results indicate that AgNPs 
could inhibit the growth of H3N2 IFV, and hemagglutination 
activity is likely to be involved in the mechanism of antivi-
ral effects. AgNPs might interfere with binding of the viral 
hemagglutinin to cellular receptors and inhibit the viral entry 
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Figure 7 Intranasal agNP administration protected the mice from infection with h3N2 IFV. (A) survival rate changes (%). (B) Changes in body weight (%). (C and D) lung 
ratio and titers at day 6 post–infection. (E) Pathologic lesions of lung tissues (a–d) represent mice treated with phosphate-buffered saline, oseltamivir, and AgNPs, and the 
virus control group, respectively). Arrows indicate lymphocytic infiltration BALB/c mice (n=8) were infected with h3N2 IFV 24 hours prior to intranasal administration of 
AgNPs (5 mg/kg) and oseltamivir (25 mg/kg) on three occasions over a 24-hour interval. The survival rate and body weight changes were monitored daily. Growth of virus 
was examined by hemagglutination assay. Pathologic lung lesions were identified by histochemistry assay. 
Notes: Values shown are the mean ± standard deviation for three independent experiments (each group n=8). (C) The data are significantly different at §P,0.05 and ¶P.0.05 
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Abbreviations: agNPs, silver nanoparticles; IFV, influenza virus. HA, hemagglutination.
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process, which is consistent with the observation that AgNPs 
can inhibit vaccinia virus infection by preventing entry of 
the virus into host cells via a  macropinocytosis-dependent 
mechanism.25 Each hemagglutinin molecule has two disul-
fide bonds, which can be broken to expose receptor binding 
sites that are available for interacting with host cells.26 These 
exposed disulfide bonds are attractive sites for interaction 
between AgNPs and the virus, and thereby exhibit antivi-
ral activity when the receptor binding sites are blocked by 
AgNPs.27 Consistent with the present study, other research-
ers have shown that AgNPs 1–10 nm in size are able to 
attach to the virus and bind to the exposed sulfur-bearing 
residues of gp120 glycoprotein, contributing to inhibition of 
binding between the virus and host cells.14 It has also been 
documented that AgNPs exert anti-human immunodeficiency 
virus activity by binding to gp120 glycoprotein through the 
prevention of receptor-dependent virion binding, fusion, and 
infectivity, at both the early viral replication and post-entry 
stages.28
To confirm further our findings in vitro, H3N2-infected 
mice were post-treated with AgNPs or oseltamivir on three 
occasions over a 24-hour interval, and lung virus titers were 
evaluated after the killing the mice. Post-treatment with 
AgNPs or oseltamivir resulted in significantly decreased lung 
viral titers compared with titers in untreated mice (approxi-
mately 3-fold log
10
). This obvious control of lung viral rep-
lication indicates that AgNPs may play an important role in 
inhibiting virus growth in vivo compared with oseltamivir, 
suggesting that AgNPs may have an obvious anti-H3N2 effect 
in vivo. In support of this conclusion, lung homogenates were 
collected and subpassaged into mice via intranasal infection. 
Mice infected with lung homogenates derived from mice 
treated with AgNPs and oseltamivir were able to maintain 
a longer life than that of the free IFV infected mice. In this 
regard, our data demonstrate that intranasal administration of 
AgNPs is able to posit AgNPs act as a strong virucidal agent 
in vivo for prevention of H3N2 virus infection.
Influenza viral envelopes are largely derived from host 
cell membranes, and functionally served for viral entrance 
to host cells.29 To this end, the disruption of viral envelopes 
and capsids may help to detach virion binding to the cell 
surface, resulting in disinfection of viruses to the host. In 
this study, negative staining of AgNPs-treated H3N2 viruses 
was morphologically analyzed. It was found that most of the 
H3N2 viral structures were ill-defined after treatment with 
AgNPs from 30 minutes to 2 hours. These results suggest 
that AgNPs may have a negative impact on entry of the virus 
into host cells. AgNPs may directly interact with H3N2 viral 
capsid proteins and thereby inhibit receptor-mediated viral 
binding and endocytosis. Consistent with our study, Speshock 
et al reported that AgNPs can bind to viral glycoproteins 
and inactivate viral functions prior to interaction with host 
cells.17 In addition, round AgNPs 10 nm in diameter could 
block the binding and penetration of Monkeypox virus into 
host cells.16 The change in H3N2 morphology may provide a 
possible mechanism that the effect of AgNPs on IFV particles 
might be virucidal rather than antiviral, thereby contributing 
to the interference of virus binding, diffusing, and further 
replication by AgNPs.
AgNPs have been known to be effective in inhibiting 
various viruses in vitro, while the in vivo effects of AgNPs 
on influenza virus infection remain largely unknown. In 
this study, we investigated the inhibitory effects of AgNPs 
on influenza virus via intranasal delivery using an H3N2 
virus-infected mouse model. The protection of AgNPs 
post-treatment via intranasal administration was strong 
indicating the significant resistance of AgNPs to H3N2 
virus infection. AgNP-treated mice did not show obvious 
illness symptoms even though minor body weight loss 
was observed. Intranasal administration of AgNPs and 
oseltamivir to H3N2 virus-infected mice had a signifi-
cant survival benefit, and only minor pathologic lesions 
were seen in lung tissues. It was reported that daily use 
of  ginseng could significantly increase vaccination effi-
ciency and reduce cases of influenza symptoms.1 Further 
studies should explore whether a combination of AgNPs 
and vaccination could improve the live efficacy against 
influenza infection. The molecular mechanism underly-
ing the antiviral activity of AgNPs remains unknown. 
Soluble Ag+ ions can strongly inhibit growth of pathogens 
by downregulation of respiratory enzymes, suppression 
of electron transport components, and interference with 
the functions of DNA.30 The results of the present study 
suggest that AgNPs possess multiple mechanisms acting 
against IFV infection by acting either as direct virucidal 
particles or antiviral agents. Further study of the antiviral 
mechanics involved is required.
Table 1 Protective effects of agNPs on h3N2 IFV infected mice 
in secondary passage in vivo
Groups Previous 
injected dose
Survivors/ 
total
Survival, 
days
Survival 
(%)
IFV Free 0/8 6 0
agNPs 5 mg/kg 8/8 14 100
Oseltamivir 20 mg/kg 8/8 14 100
Abbreviations: H3N2, A/Human/Hubei/3/2005; IFV, influenza virus; AgNPs, silver 
nanoparticles; IFV, influenza virus.
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Conclusion
In this study, we used H3N2 IFV as a virus model to 
 investigate the inhibitory activity of AgNPs against the influ-
enza virus by performing a series of assays in vitro (MTT, 
hemagglutinin, flow cytometry, immunofluorescence, and 
TEM) and in vivo (an IFV-infected mouse model). In vitro, 
AgNPs significantly protected cells against viral infection by 
increasing their live viability and protecting against CPEs, 
inhibiting growth of the virus, and decreasing the cellular 
apoptosis induced by H3N2 IFV. AgNPs interacted with 
viral particles and destroyed their morphologic structures 
in a time-dependent manner. In addition, intranasal AgNP 
administration significantly enhanced survival in mice, pre-
vented virus growth in their lungs, inhibited the development 
of pathologic lung lesions, and had a marked survival benefit 
on secondary passage. Taken together, the results indicate that 
AgNPs have promising antiviral activity against H3N2 IFV 
through multiple mechanisms, demonstrating that develop-
ment of optimized AgNPs and further investigation of their 
relevant antiviral mechanisms will be critical for controlling 
influenza outbreaks.
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